Programm & Abstracts                 "Innovationen in der Augenheilkunde"

Aktuelle Tagungsinformationen
   News and Updates

Anmeldung zur Tagung
   Registration
Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Collateral Events
Rahmenprogramm
   Social program
Jubiläumsparty
   Jubilee Party
DOG Information
   DOG Information
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Ausstellerliste
   Exhibitors
Sponsoren
   Sponsors
Teilnahmegebühren
   Registration fees
Impressum



DOG Homepage

The CALDIRET-Study - A Randomized Double-blinded Multi-Center-Study. Can Calciumdobesilate Delay the Formation of Clinically Significant Diabetic Macular Edema?

Ulbig M., Kampik A.,
Ludwig-Maximilians-Universität München, Klinikum Innenstadt, Augenklinik (München)

Objective: Doxium®, Calciumdobesilate is thought to restore the blood retinal barrier by protection versus sorbitol in vascular endothelial cells and to improve on retinal circulation. The Caldiret Study was designed to show a beneficial effect.
Patients and methods: 635 adult onset diabetics with an age from 40 to 68 years and satisfactory control measured by HbA1c levels and mild to moderate NPDR were recruited. Patients had no Doxium intake during previous 12 months. Diastolic blood pressure was below 100 mm Hg and proteinuria between 20 and 200 mg/l. Informed consent was provided. Exclusion criteria were new vessels, signs of macular edema, media opacities precluding high quality fundus stereo photography to ETDRS standards, previous laser treatment or vitrectomy for diabetic retinopathy, pregnancy, and need for hemodialysis. Fundus photographs were evaluated in one reading center.
Results: The study started in August 1996 and is scheduled to last until 2003. Patients are photographed and examined twice a year. Overall 40 centers are involved, 21 in Germany, Austria, and Switzerland, and 19 in eastern Europe. All patients were enrolled by the end of 1998. Daily 1500 mg of Calciumdobesilate or placebo are administered. Mean HbA1c-levels were 8.1 in Germany, Austria, and Switzerland, and 8.3 in eastern Europe. Patients' mean age was 58 years at inclusion. By April 2002 129 endpoints (clinically significant macular edema) had occurred, 174 patients had been withdrawn, and 303 were ongoing.
Conclusions: The Caldiret-study enrolled the required number of patients. The occurrence of clinical endpoints is satisfactory. There was no difference in quality of control of diabetes in western and eastern Europe at entry. We are looking forward to answer interesting epidemiological aspects of diabetic macular edema and the question as to whether calciumdobesilate is beneficial in the prevention.

Zurück/Back